Ultime notizie per Cue Biopharma (NASDAQ:CUE) Azioni

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Cue Biopharma Inc

Cuentas Inc

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Cue Energy Resources Ltd

Cue Health Inc

As interest in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapies</a> (PATs) grows, so does the need for clearer safety guidelines. Psychedelic treatments using substances like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, <a href="https://www.benzinga.com/topic/lsd">LSD</a>, and <a href="https://www.benzinga.com/topic/mdma">MDMA</a> are being explored for mental health issues like depression and PTSD, showing promising results. The FDA has granted breakthrough therapy status to some, but its recent <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">rejection of MDMA for PTSD</a> due to safety concerns highlights the need for standardized assessments of adverse events (AEs) in these therapies. 
While research has largely focused on their benefits, assessing the risks and AEs related to these therapies has not been as thorough. A new framework <a href="https://journals.sagepub.com/doi/10.1177/02698811241265756#con1">published</a> in the Journal of Psychopharmacology seeks to change that, introducing a comprehensive approach for identifying, monitoring, and reporting potential negative effects specific to psychedelic therapies.
<h3 class="wp-block-heading">The Need For Tailored Adverse Event Reporting</h3>
Psychedelic-assisted therapies are different from traditional treatments because they combine the effects of powerful psychedelic substances with psychotherapy. This combination can lead to <a href="https://www.benzinga.com/markets/cannabis/24/08/40528986/psychedelic-trips-resemble-near-death-experiences-new-study-shows-what-does-it-mean">unique experiences</a> such as intense visual effects, spiritual insights, and deep psychological changes that standard safety assessments often overlook. Current guidelines for reporting side effects in clinical trials, like those in the Medical Dictionary for Regulatory Activities, may not fully capture these unique effects. 
Author Roman Palitsky and his team have created a new framework to address this gap. It outlines 54 potential adverse events specific to psychedelic therapies, covering physical, mental, and spiritual impacts. &#8220;Psychedelic therapies require specialized guidelines because they blend strong pharmacological effects with psychotherapy,&#8221; said Palitsky. This new approach aims to provide a more detailed understanding of the risks, which can help researchers and clinicians better protect patients.
<h3 class="wp-block-heading">Challenges Of Identifying Adverse Events</h3>
A key issue in assessing side effects in psychedelic therapy is underreporting. Patients may avoid mentioning negative experiences, especially if they support the push to <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalize psychedelics</a>. Therapists may also overlook or misinterpret adverse events due to their own expectations about the treatment&#8217;s benefits.
The framework suggests using self-reports, clinician observations and feedback from those close to the patient to better assess side effects. It distinguishes between normal discomfort, like facing tough emotions and genuine adverse events, such as lasting anxiety or depression. In some cases, these issues can lead to severe outcomes, as seen in some psilocybin trials.
<h3 class="wp-block-heading">New Areas of Focus for Safety Assessments</h3>
The framework introduces several new categories for tracking adverse events specific to psychedelic therapies: Psychospiritual Issues, which involve negative impacts on spiritual beliefs or existential well-being; Interpersonal Issues, such as changes in social behavior due to psychedelics' effects on brain systems; Behavioral Changes, like disrupted sleep or increased substance use and Cultural and Epistemic Harms, which address potential conflicts with a patient's cultural or religious beliefs. These categories highlight the unique risks of combining psychedelics and psychotherapy, offering a more detailed approach to patient safety.
<h3 class="wp-block-heading">Importance of Long-Term Monitoring</h3>
The framework emphasizes the need for extended follow-up, as many adverse effects may not become apparent until weeks or even months after the therapy session. This long-term monitoring is critical because the changes induced by psychedelics can have <a href="https://www.benzinga.com/markets/cannabis/22/03/25994197/study-finds-psilocybin-anti-depression-effects-last-at-least-one-year">lasting effects</a> on a person's worldview, relationships and overall well-being.
&#8220;Changes brought about by psychedelic experiences can take time to fully emerge, making long-term follow-up essential for accurate assessment,&#8221; the authors suggest. They recommend assessing adverse events for at least six months after treatment, allowing researchers to capture any delayed effects that might otherwise go unnoticed.
<h3 class="wp-block-heading">Moving Towards Safer Psychedelic Therapies</h3>
This new framework is a significant advancement in psychedelic research, offering a structured approach to track side effects more effectively. By identifying a wider range of risks, it helps clinicians make informed decisions and improve patient safety. Future studies will need to validate and refine the framework to ensure it captures all potential adverse events. 
In summary, Palitsky&#8217;s framework provides a comprehensive method to standardize safety reporting in psychedelic therapies, playing a key role in making these treatments safer and more reliable as they move toward mainstream use.
Cover image made with AI

Cannabis

News

Psychedelics

Health Care

New Study Charts Adverse Events In Psychedelic-Assisted Therapies

Leading cryptocurrencies pulled back Thursday as Federal Reserve Chair Jerome Powell's remarks <a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates">poured cold water on rate cut optimism.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:30 p.m. ET)</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>-2.23%</td>
<td>$88,282.07</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>-3.55%</td>
<td>$3,091.21</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>-4.46%</td>
<td>$0.3726</td>
</tr>
</tbody>
</table>
</figure>
What Happened: Bitcoin rose past $91,000 early morning hours, only to slip below $88,000 after the market close, resulting in more than a 2% decline over the last 24 hours.
Ethereum sharply descended from $3,240 to $3,040 over the day. Over the week, the second-largest cryptocurrency gained 3.89%, significantly trailing its senior partner, which was up over 15%.
More than $505 million worth of positions were liquidated in the last 24 hours, with nearly $350 million in upside bets getting wiped out.
Bitcoin's Open Interest (OI) dropped 0.82% in the last 24 hours. A drop in OI, alongside a drop in spot price, also pointed toward long liquidations.
That said, the number of traders betting in favor of Bitcoin's price rally rose in comparison to those shorting the asset, according to the Long/Short Ratio.
The "Extreme Greed" sentiment weakened from 88 to 80 as a result of the retrace, according to the Cryptocurrency Fear and Greed Index.
Top Gainers (24-Hours)
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 7:30 p.m. ET)</td>
</tr>
<tr>
<td>Act I: The AI Prophecy (ACT)</td>
<td>+32.46%</td>
<td>$0.8424</td>
</tr>
<tr>
<td>MANTRA (OM)</td>
<td>+20.63%</td>
<td>$1.68</td>
</tr>
<tr>
<td>XRP (XRP)</td>
<td>+13.42%</td>
<td>$0.786</td>
</tr>
</tbody>
</table>
</figure>
The global cryptocurrency market capitalization stood at $2.92 trillion, declining 1.53% in the last 24 hours.
Stocks closed in the red on Thursday. The Dow Jones Industrial Average slipped 207.33 points, or 0.47%, to close at 43,750.86. The S&amp;P 500 lost 0.60% to end at 5,949.17. The tech-focused Nasdaq Composite dipped 0.64% to 19,107.65, marking its third straight losing day.
The sell-offs followed Fed Chair Powell&#8217;s statements that the central bank needn't "be in a hurry" to cut rates given the strength of the economy. 
The cautious remarks triggered a sharp decline in rate cut expectations during next month's FOMC meeting, from 82% to 59%,&nbsp; <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according </a>to data from the CME FedWatch tool&nbsp;
See More: <a href="https://www.benzinga.com/money/best-crypto-scanners">Best Cryptocurrency Scanners</a>
Analyst Notes: Popular cryptocurrency analyst Rekt Capital described Bitcoin dips early on in the price discovery phase as "high-probability opportunities."
"As the parabolic phase goes on, however, the pullbacks will become increasingly riskier for dollar-cost-averaging Good thing we&#8217;re so early in the parabolic upside phase," the analyst remarked.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> dips early on in Price Discovery are high-probability opportunities As the Parabolic Phase goes on however, the pullbacks will become increasingly riskier for dollar-cost-averaging Good thing we&#39;re so early in the Parabolic Upside phase<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://twitter.com/hashtag/Crypto?src=hash&amp;ref_src=twsrc%5Etfw">#Crypto</a> <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>
&mdash; Rekt Capital (@rektcapital) <a href="https://twitter.com/rektcapital/status/1857094023690797475?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On-chain analytics firm CryptoQuant said that high stablecoin inflows were driving the Bitcoin bull market.
"There is a continuation of a higher-than-normal influx of stablecoins. This suggests that barring any additional news flow, the Bitcoin bull market has not yet ended," the firm said, indicating that more upsides could follow.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin Bull Market Fueled by Stablecoin Inflows: Will the Uptrend Continue? "There is a continuation of a higher-than-normal influx of stablecoins. This suggests that barring any additional news flow, the <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> bull market has not yet ended." – By <a href="https://twitter.com/theKriptolik?ref_src=twsrc%5Etfw">@theKriptolik</a> Link &#x1f447;… <a href="https://t.co/SAEnv6oxUD">pic.twitter.com/SAEnv6oxUD</a>
&mdash; CryptoQuant.com (@cryptoquant_com) <a href="https://twitter.com/cryptoquant_com/status/1857194154310214060?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Photo by CMP_NZ on Shutterstock
Read Next:    
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41959476/fbi-raids-polymarket-ceo-over-crypto-betting-platforms-us-activities-he-fires-back-in-the-face-of-adversity-we-build">FBI Raids Polymarket CEO Over Crypto Betting Platform&#8217;s US Activities — He Fires Back: &#8216;In The Face Of Adversity, We Build&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

Trading Ideas

$BTC

$DOGE

$ETH

Bitcoin, Ethereum, Dogecoin Take A U-Turn As Jerome Powell's Statements Dampen Rate Cut Expectations: Analytics Firm Explains Why BTC Bull Market Has Not Yet Ended

Investment veteran Gary Black cautions that Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will lose the most if the $7,500 federal electric vehicle tax credit is eliminated, citing the company&#8217;s overwhelming dependence on <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">EV sales compared to traditional automakers</a>.
What Happened: Black, managing partner at The Future Fund LLC, points to Tesla&#8217;s recent history of price-related challenges as evidence for his concern. &#8220;Tesla&#8217;s earnings power declined by 45% and shares fell by 70% in 15 months&#8221; following price cuts of 15-20% in late 2022 and 2023, he noted on social media platform X.
The potential loss of the tax credit could effectively increase Tesla&#8217;s U.S. vehicle prices by 20%, affecting approximately 30% of the company&#8217;s global sales volume. Black emphasizes that Tesla&#8217;s vulnerability stems from its business model, where electric vehicles represent about 80% of revenue.
&#8220;No one else has anywhere near that degree of exposure to EVs,&#8221; Black wrote, contrasting Tesla&#8217;s position with traditional automakers. He dismisses concerns about the impact on legacy manufacturers, noting that companies like General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) saw earnings growth during Tesla&#8217;s recent downturn.
Black&#8217;s analysis challenges some Tesla supporters who suggest the credit&#8217;s removal would primarily hurt traditional automakers. He argues that mathematical analysis doesn&#8217;t support this view, pointing out that EVs typically constitute only 5-10% of legacy automakers&#8217; business.
&#8220;Why would raising price on 5-10% of legacy auto's business bankrupt them? C'mon folks &#8211; please do the math,&#8221; Black wrote. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I love when <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> bulls try to spin negative industry news as good for TSLA but bad for everyone else. When TSLA cut prices by 15-20% in late-2022 and 2023 — which sparked a price war — I was one of the few who warned repeatedly that TSLA earnings would get decimated, while mgmt… <a href="https://t.co/c03qw3c53V">https://t.co/c03qw3c53V</a> <a href="https://t.co/cwXIrzmsTI">pic.twitter.com/cwXIrzmsTI</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1857186024977543546?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">Warren Buffett&#8217;s Berkshire Hathaway Slashes Apple, BofA Holdings, Adds Domino&#8217;s Pizza In Q3</a>
Why It Matters: The potential elimination of the $7,500 EV tax credit has been a topic of concern for Tesla and the EV industry as a whole. Despite the negative implications, some analysts believe that this move could be <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">beneficial for Tesla</a>.
Meanwhile, Tesla&#8217;s stock has been on the rise since the 2024 presidential election, with Elon Musk&#8216;s endorsement of President-elect Donald Trump being seen as a <a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this">significant factor in this growth</a>.
Furthermore, the recent announcement of Musk as the co-lead for the Department of Government Efficiency (DOGE) has been <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41968621/analysts-divided-about-impact-of-elon-musk-co-leading-doge-on-tesla-stock-heres-what-bulls-and-bears-have-to-say">met with mixed reactions</a> from analysts, with Black suggesting that this appointment may not have a significant impact on Tesla&#8217;s stock.
Price Action: Tesla stock closed at $311.18 on Thursday, down 5.77% for the day. In after-hours trading, Tesla slipped a further 1.15%. Despite recent drops, Tesla&#8217;s stock has gained 25.26% year to date, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<a href="https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-position-broadcom">Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom</a>
Image via Tesla
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

TSLA

Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: 'Do The Math'

Editor&#8217;s Note: This article has been updated to exclude references to CEO Kyle Kazan's past experience, as they were not directly relevant to the focus of the story.
Vertically integrated Glass House Brands Inc. (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTCQX">GLASF</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GHBWF#OTCQX">GHBWF</a>) reported its financial results Wednesday for the third quarter ended Sept. 30, 2024.
The cannabis company is focused on strategic growth initiatives, including expanding production capacity, improving cost efficiency and positioning itself to weather challenges in the California weed market. However, retail pricing pressures may continue to affect margins in the near term.
"While we expect lower prices to continue in the short-term, longer-term we expect Glass House will benefit, as our Company is built to weather market cycles and emerge even stronger," said Kyle Kazan, co-founder, chair, CEO and a <a href="https://www.benzinga.com/markets/cannabis/24/08/40444315/california-company-led-by-ex-police-officer-turned-cannabis-ceo-could-pivot-into-hemp-space">former Los Angeles police officer</a>.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Net revenue totaled $63.8 million, up 32% year-over-year from $48.2 million and 18% sequentially from the previous quarter.</li>
<li>Retail revenue amounted to $11.2 million, a slight increase from the prior period ($10.9 million) and the third quarter of 2023 ($10.1 million).</li>
<li>CPG revenue amounted to $4.8 million, up 11% YoY and 20% sequentially.</li>
<li>Gross profit amounted to $33.4 million, compared to $26 million in the prior year's period and $28.7 million in the second quarter of this fiscal year.</li>
<li>Gross margin was 52%, down slightly from 54% year-over-year and 53% from the previous quarter.</li>
<li>Adjusted EBITDA came in positive at a record $20.4 million, up from $10.7 million in the third quarter of 2023 and $12.4 million in the prior period.</li>
<li>Operating cash flow was $13.2 million, representing a 45% increase year-over-year.</li>
<li>The company had $35.1 million in cash and restricted cash as of Sept. 30, 2024, up from $25.9 million in the second quarter of 2024.</li>
</ul>
<h3 class="wp-block-heading">Operational Developments</h3>
<ul>
<li>The company&#8217;s retail strategic pricing plan has driven increased foot traffic and higher consumer loyalty.</li>
<li>Glass House is working on the Greenhouse 2 retrofit to increase production capacity by 275,000 pounds annually by the fourth quarter of 2025, aiming for a cost target of $100 per pound.</li>
<li>The company has obtained a hemp license and is testing strains, with plans to decide on large-scale production by the second quarter of 2025.</li>
<li>Glass House successfully had the Catalyst lawsuit dismissed, while Hector De La Torre returned to serve on the board of directors.</li>
</ul>
<h3 class="wp-block-heading">2024 Outlook</h3>
<ul>
<li>The company expects $47 million to $49 million in fourth-quarter revenue, representing a 19% year-over-year increase.</li>
<li>In terms of biomass production, the company provided a guidance of 160,000 to 165,000 pounds, representing 57% year-over-year growth.</li>
<li>The company forecasted adjusted EBITDA of $3 million to $5 million for the fourth quarter of fiscal 2024.</li>
<li>Capex is projected at roughly $6 million, with $5 million allocated to Phase III expansion.</li>
<li>Under the At-The-Market (ATM) program, the company can raise up to $25 million for Phase III expansion.</li>
</ul>
<h3 class="wp-block-heading">GLASF Price Action</h3>
Glass House Brands' shares traded 0.61% lower at $8.1 per share after the market close on Wednesday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40366081/size-matters-glass-houses-150-000-pound-harvest-drives-record-53-9m-revenue-in-q2-2024">Size Matters: Glass House&#8217;s 150,000-Pound Harvest Drives Record $53.9M Revenue In Q2 2024</a></li>
</ul>

Earnings

GHBWF

GLASF

California Weed Co. Glass House Brands Reports 32% YoY Q3 Revenue Growth (UPDATED)

On Thursday, Ark Invest, led by Cathie Wood, made significant trades in Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), according to the firm&#8217;s daily trade data.
The Amazon Trade
Ark picked up 28,509 Amazon shares for ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), Ark Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) in a transaction valued at $6.03 million. As of Thursday, Amazon&#8217;s stock closed at $211.48, reflecting a decrease of 1.22%. 
Ark Invest&#8217;s move on Amazon comes in the wake of the e-commerce giant&#8217;s recent launch of a low-cost online storefront, &#8220;Haul&#8221;, designed to <a href="https://www.benzinga.com/news/global/24/11/41949051/whats-going-on-with-amazon-stock-wednesday-2">compete with Chinese e-commerce platforms</a>. According to a report, Amazon initiated discussions with China-based sellers earlier this year about offering a similar service. The exact details of Ark&#8217;s trade in Amazon were not disclosed in the data provided.
The Rocket Lab Trade
Ark Invest sold 627,775 shares in Rocket Lab, valued at almost $10.09 million. The trades were made through the ARKQ and ARKX ETFs. 
This sale followed a significant surge in Rocket Lab&#8217;s shares, which shot up over 28% to $18.83 on Wednesday. As of Thursday, Rocket Lab&#8217;s stock closed at $17.36, reflecting a decrease of 7.81%.
The earlier surge was triggered by the company&#8217;s announcement of better-than-expected <a href="https://www.benzinga.com/24/11/41932662/why-rocket-lab-shares-are-trading-higher-by-around-29-here-are-20-stocks-moving-premarket">third-quarter financial results</a>, a multi-launch agreement with a confidential commercial satellite constellation operator, and a federal defense contract worth up to $8 million.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41963342/elizabeth-warrens-sarcastic-take-on-doges-split-leadership-gets-slammed-by-elon-musk-unlike-you-neither-of-us-are-being-paid?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elizabeth Warren&#8217;s Sarcastic Take On DOGE&#8217;s Split Leadership Gets Slammed By Elon Musk: &#8216;Unlike You, Neither Of Us Are Being Paid&#8217;</a>
Other Key Trades: 
<ul>
<li>Ark continued to purchase shares of eVTOL companies like Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and Joby Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) on Thursday. The firm picked up 409474 ACHR shares worth $1.76 million and 303674 JOBY shares worth $1.8 million.</li>
<li>The Wood-led firm purchased 2,706 shares of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), worth $375,701, through its ARKX fund.</li>
<li>Ark Invest bought shares of Schrodinger Inc (SDGR) and shares of Guardant Health Inc (GH) through its ARK Genomic Revolution ETF (ARKG).</li>
<li>The firm also sold shares of Moderna Inc (MRNA) and shares of Repare Therapeutics Inc (RPTX) through the same ETF.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41890968/bitcoin-kisses-89500-ethereum-dogecoin-extend-trump-victory-rally-how-long-before-btc-hits-100000-analysts-reveal?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Hovers Around $90K, Ethereum, Dogecoin Extend Trump Victory Rally: How Long Before BTC Hits $100,000? Analysts Reveal</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

ETFs

ACHR

AMZN

ARKF

ARKQ

ARKX

JOBY

RKLB

Cathie Wood Keeps Betting On Amazon's 'Haul' Play: Ark Loads Up $6M Worth Of Shares

Agrify Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>), a <a href="http://benzinga.com/cannabis">cannabis</a> and hemp solutions provider, reported its third quarter 2024 financial results Thursday, revealing a $1.9 million revenue, down from $3.1 million a year ago. The company posted a net loss of $18.6 million, largely driven by a $15 million change in the fair value of warrant liabilities.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue: $1.9 million, compared to $3.1 million in Q3 2023.</li>
<li>Net Loss: $18.6 million, primarily due to a $15 million change in the fair value of warrant liabilities, compared to a net loss of $2.1 million in Q3 2023.</li>
<li>Gross Profit: $0.2 million, compared to $1.0 million in Q3 2023.</li>
<li>Adjusted EBITDA: Not specified in the earnings report.</li>
</ul>
<h3 class="wp-block-heading">New Financing Strengthens Agrify&#8217;s Balance Sheet</h3>
Despite ongoing financial struggles, Agrify <a href="https://www.benzinga.com/markets/cannabis/24/11/41760263/marijuana-growing-solution-provider-agrify-gets-20m-boost-from-green-thumb-to-power-up-cannabis-">secured a $20 million convertible note financing</a> from Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>), with an initial draw of $10 million, providing a crucial liquidity boost. This funding aims to strengthen the company&#8217;s balance sheet and support future growth opportunities.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
As of November 14, the company has approximately 1.5 million shares of common stock outstanding and 6.3 million warrants.
<h3 class="wp-block-heading">New CEO's Commentary</h3>
Ben Kovler, recently appointed as chairman and interim CEO emphasized a strategic shift for Agrify. &#8220;Today really is Day One at Agrify,&#8221; Kovler <a href="https://www.globenewswire.com/en/news-release/2024/11/14/2981578/0/en/Agrify-Corporation-Announces-Results-for-Third-Quarter-2024.htmlhttps://www.globenewswire.com/en/news-release/2024/11/14/2981578/0/en/Agrify-Corporation-Announces-Results-for-Third-Quarter-2024.html">stated</a>, pointing to the company's renewed focus on market trends. 
"The hemp and cannabis industries are evolving fast and Agrify's fortified balance sheet is ready to move on opportunities. We have a deep understanding of the consumer and plan to leverage that strength today to build Agrify's value for tomorrow," Kovler added.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41925928/weedmaps-net-income-surges-312-yoy-cash-reserves-up-31">Weedmaps Net Income Surges 312% YOY, Cash Reserves Up 31%</a>
<h3 class="wp-block-heading">Agrify Expands Into Hemp THC Beverage Market</h3>
Agrify also announced a non-binding letter of intent to acquire Señorita, a brand specializing in <a href="http://benzinga.com/topic/hemp">hemp-derived</a> THC beverages, underscoring the company&#8217;s aim to diversify its product portfolio. This acquisition is expected to strengthen Agrify's position in the cannabis beverage market, <a href="https://www.benzinga.com/markets/cannabis/24/10/41356399/thc-beverages-could-revive-struggling-alcohol-industry-expert-says-partying-stress-and-anxiety-h">a segment gaining momentum</a> across the U.S.
AGFY Price Action AGFY's shares traded 30.49% higher at $13.61 per share at the market close Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41994550/trumps-national-intelligence-pick-is-cannabis-advocate-tulsi-gabbard-critics-say-former-congresswoman-parrots-russia-propaganda">Trump&#8217;s National Intelligence Pick Is Cannabis Advocate Tulsi Gabbard: Critics Say Former Congresswoman Parrots Russia Propaganda</a></li>
</ul>

AGFY

GTBIF

Agrify's Q3 Revenue Drop, $18.6M Loss Amid New Leadership

Speaking at the Benzinga Cannabis Market Spotlight in Anaheim this week, Kyle Kazan, CEO of Glass House Brands (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTC">GLASF</a>), delivered a candid assessment of California&#8217;s <a href="http://benzinga.com/topic/california-cannabis">cannabis industry</a> and shared his strategic outlook on federal cannabis policy. 
Kazan, <a href="https://www.benzinga.com/markets/cannabis/24/07/40024424/ex-police-officer-turned-cannabis-ceo-calls-for-federal-marijuana-de-scheduling-in-letter-to-har">a prominent voice in the industry</a>, emphasized the importance of collaboration among cannabis businesses and offered a hopeful yet pragmatic take on the potential shifts in cannabis regulation at both the state and federal levels.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Joe Rogan, Elon Musk, RFK Jr.: The Pro-Cannabis Voices Shaping Trump's Policies – Glass House CEO" width="500" height="281" src="https://www.youtube.com/embed/XsbUY-UnVOM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<figcaption class="wp-element-caption">Kyle Kazan, CEO of Glass House Brands, at the Benzinga Cannabis Market Spotlight in Anaheim, California</figcaption></figure>
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41981887/california-weed-co-led-by-former-la-cop-reports-32-yoy-q3-revenue-growth">California Weed Co. Led By Former LA Cop Reports 32% YoY Q3 Revenue Growth</a> 
<h3 class="wp-block-heading">California: The Toughest Market In Cannabis</h3>
"If you can make it in California, you can make it anywhere," Kazan said, underscoring the unique challenges posed by California's <a href="https://www.benzinga.com/markets/cannabis/24/10/41547103/new-rules-old-challenges-californias-cannabis-industry-grapples-with-regulations">regulatory environment</a> and market dynamics. He pointed to the difficulty of succeeding in the state's <a href="https://www.benzinga.com/news/events/24/11/41886925/california-cannabis-industry-titans-headline-benzingas-anaheim-event-tues-nov-12">fiercely competitive market</a> and highlighted the resilience required for businesses to thrive.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">A Call For Industry Unity Amid Policy Challenges</h3>
Despite the competitive nature of the industry, Kazan urged stakeholders to set aside differences and collaborate on advancing policy reforms. He highlighted missed opportunities in the past and warned of tougher market conditions if the sector does not unify.
"Let's find that Venn diagram where we can work together to move better policy forward in this state and also federally," Kazan said.
<h3 class="wp-block-heading">Navigating Election Aftermath: Optimism Amid Uncertainty</h3>
Addressing the implications of the recent election, Kazan struck a balanced tone, acknowledging the emotional landscape while emphasizing a strategic approach. He noted that Glass House Brands has maintained bipartisan engagement, making inroads with both Kamala Harris and Donald Trump's campaigns.&nbsp;
However, he expressed optimism about potential reform, referencing <a href="https://www.benzinga.com/markets/cannabis/24/01/36788077/trumps-support-bidens-los-angeles-weldon-angelos-weed-">Trump's pardons</a> of Weldon Angelos and Harry O as promising indicators of his stance on cannabis.
Kazan also pointed to President-elect Trump's support for states&#8217; rights and his <a href="https://www.benzinga.com/markets/cannabis/24/08/40666944/donald-trump-supports-cannabis-legalization-in-florida-game-changer-and-huge-blow-to-ron-desanti">endorsement of Florida's cannabis amendment</a> as positive signals. "We've been assured that's his stance on cannabis. He came out publicly for Amendment 3 in Florida. Why would he not do that for the other 49 states?"
<h3 class="wp-block-heading">Investor Concerns And Future Outlook For Cannabis</h3>
While Kazan acknowledged the uncertainty that investors face given the <a href="https://www.benzinga.com/markets/cannabis/24/09/40846480/cannabis-experts-say-weed-reform-is-a-race-against-time-is-the-dea-delaying-bidens-rescheduling-">unclear regulatory path ahead</a>, he remained upbeat about the long-term prospects. He cited the growing influence of pro-cannabis voices in Trump's inner circle, including figures like Elon Musk, Joe Rogan, <a href="https://www.benzinga.com/news/legal/24/11/41994550/trumps-national-intelligence-pick-is-cannabis-advocate-tulsi-gabbard-critics-say-former-congresswoman-parrots-russia-propaganda">Tulsi Gabbard </a>and <a href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics">Robert F. Kennedy Jr.</a> as reasons for optimism. 
"Until the cabinet is named and things happen, there's concern, but I'm very positive," Kazan concluded, noting that the overall trajectory remains promising for the industry.
The Benzinga Cannabis Market Spotlight in Anaheim brought together industry leaders to discuss trends, investment strategies, and the future of cannabis in California's evolving landscape.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41994550/trumps-national-intelligence-pick-is-cannabis-advocate-tulsi-gabbard-critics-say-former-congresswoman-parrots-russia-propaganda">Trump&#8217;s National Intelligence Pick Is Cannabis Advocate Tulsi Gabbard: Critics Say Former Congresswoman Parrots Russia Propaganda</a></li>
</ul>

Events

Interview

Glass House CEO Calls For Unity In California Cannabis Market, Optimistic About Federal Reform

The Joe Rogan Experience or JRE premiered exclusively on Spotify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) in Sept. 2020 as part of a <a href="https://www.benzinga.com/news/22/02/25708354/joe-rogans-deal-with-spotify-worth-at-least-double-of-what-was-previously-reported-nyt">multi-year deal</a> reportedly valued at $200 million. This deal wasn&#8217;t just big news for podcasting fans—it was a major moment for investors, too.
Rogan&#8217;s Impact On Spotify&#8217;s Growth
Spotify's exclusive deal with Rogan was a bet that paid off in multiple ways. Since the partnership, podcast consumption on the platform skyrocketed by 232%, according to the company.
Advertisers took notice, fueling a 2023 revenue increase of 80% since 2021. Rogan's show, consistently the world's most-streamed podcast, played a major role in turning Spotify into a podcasting giant.
Rogan&#8217;s podcast also held the top spot on <a href="https://www.benzinga.com/general/entertainment/23/11/36004998/joe-rogan-tops-spotifys-2023-podcasts-list-once-again-deal-likely-to-expire-in-2024-a-major">Spotify&#8217;s podcast chart</a> for the fourth year in a row in 2023.
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41959787/tradepulse-power-inflow-alert-spotify-technology-s-a-climbs-over-5-after-tradepulse-alert">Tradepulse Power Inflow Alert: Spotify Technology S.A. Climbs Over 5% After Tradepulse Alert</a>
How $1,000 Invested In Spotify Has Grown
If you had invested $1,000 in Spotify stock on Sept. 1, 2020 — the day Rogan's show debuted exclusively on the platform — that investment would now be worth approximately $1,696.
This represents a solid return of 69.7%, outpacing the broader market indexes. For context, the S&amp;P 500 rose 68.7%, and the Nasdaq Composite gained 60% over the same period.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="626" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191145/newplot-4-1.png" alt="" class="wp-image-649260" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191145/newplot-4-1.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191145/newplot-4-1-300x216.png 300w" sizes="(max-width: 626px) 100vw, 626px" /><figcaption class="wp-element-caption">Value of a $1,000 investment in Spotify stock, versus the S&amp;P 500 and Nasdaq, respectively, from Sept. 1, 2020, to Nov. 14, 2024.</figcaption></figure>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191325/newplot-8.jpeg" alt="" class="wp-image-649262" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191325/newplot-8.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14191325/newplot-8-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /><figcaption class="wp-element-caption">SPOT&#8217;s price trajectory since JRE debuted on the platform</figcaption></figure>
A New Chapter For JRE And Spotify
Earlier this year, Spotify renewed its partnership with Rogan, but the show will <a href="https://www.benzinga.com/markets/equities/24/02/36914209/spotify-inks-multiyear-deal-with-podcast-king-joe-rogan-amid-shifting-strategy">no longer be exclusive</a> to the platform, expanding to Apple, Amazon, and Google&#8217;s YouTube.
Earlier this month, Spotify released its <a href="https://www.benzinga.com/general/entertainment/24/11/41920955/spotify-stock-climbs-despite-q3-eps-revenue-misses">third-quarter financial results</a> reporting earnings of $1.46 per share, which fell short of the analyst consensus of $1.76.
Quarterly revenue came in at $3.99 billion, missing the expected $4.02 billion but reflecting an increase from $3.65 billion in the same quarter last year.
SPOT Price Action: Spotify shares ended Thursday&#8217;s session up 2.17%, closing at $477.50. In after-hours trading, however, the stock dipped slightly, settling at $476 as of the latest update, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41941113/these-analysts-increase-their-forecasts-on-spotify-following-q3-earnings">These Analysts Increase Their Forecasts On Spotify Following Q3 Earnings</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

SPOT

If You Dropped $1,000 On Spotify When Joe Rogan's Show Became An Exclusive, Here's How Much You'd Have Today

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

TKLF

Tilray Medical, a division of Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), <a href="https://www.globenewswire.com/en/news-release/2024/11/14/2981031/0/en/Tilray-Medical-Launches-its-First-Commercial-Grown-in-Germany-Medical-Cannabis-Products-Under-its-Newly-Expanded-Cultivation-License.html">announced</a> the launch of its first commercial <a href="https://www.benzinga.com/topic/germany-cannabis">medical cannabis</a> products cultivated in <a href="https://www.benzinga.com/topic/germany-cannabis">Germany</a>. 
The debut comes from its Aphria RX facility, marking a milestone under the country's recently updated cultivation regulations, MedCanG. 
<h3 class="wp-block-heading">New Cultivation License Drives Local Production</h3>
Tilray was the first company to secure the new cannabis cultivation license under MedCanG in July 2024. 
This regulatory shift allows Aphria RX to grow and manufacture a variety of popular medical cannabis strains that were previously imported. 
The indoor-grown products are expected to offer consistent quality tailored to German patients&#8217; preferences:
"Our Made in Germany premium cannabis products represent a significant step forward in delivering high-quality medical cannabis to patients," said Denise Faltischek, Tilray's chief strategy officer. "This achievement strengthens our position as a leader in cultivation, production, and distribution, while demonstrating our commitment to the German medical cannabis community."
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/41885393/germanys-govt-coalition-crisis-is-cannabis-reform-at-risk">Germany&#8217;s Govt. Coalition Crisis, Is Cannabis Reform At Risk?</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Medical Cannabis Market Shows Strong Growth</h3>
Germany's medical cannabis market is rapidly expanding, driven by increased patient adoption that came after cannabis was re-listed as a<a href="https://www.benzinga.com/government/regulations/24/11/41885393/germanys-govt-coalition-crisis-is-cannabis-reform-at-risk"> non narcotic</a> substance. 
Companies like <a href="https://www.benzinga.com/markets/cannabis/24/09/40783859/european-cannabis-producer-cantourage-reports-62-revenue-increase-projects-positive-ebitda">Cantourage</a> Group Sell, <a href="https://www.benzinga.com/markets/cannabis/24/06/39277081/german-company-launches-largest-digital-platform-for-medical-cannabis-in-all-europe">Bloomwell</a> and <a href="https://www.benzinga.com/government/regulations/24/11/41884236/exclusive-persistence-pays-off-for-only-cannabis-distributor-in-bavarias-developing-market">Drapalin</a> have reported record revenue, with projections suggesting continued robust growth. 
The shift toward local cultivation by companies like Tilray reflects the broader industry trend of securing supply chains, since most cannabis in Germany is <a href="https://www.benzinga.com/markets/cannabis/24/08/40369868/medical-marijuana-imports-in-germany-increase-51-yoy-following-reform-cannabis-clubs-still-face-">imported</a>, mainly from Canada. 
Medical cannabis, however, continues to gain traction, with sales projected to reach <a href="https://www.benzinga.com/markets/cannabis/24/09/40783859/european-cannabis-producer-cantourage-reports-62-revenue-increase-projects-positive-ebitda">$1.09 billion</a> by 2028. Recent regulatory changes have streamlined access, treating medical cannabis similarly to over-the-counter medications like ibuprofen. 
While Germany has taken steps toward partial cannabis legalization, full-scale recreational sales <a href="https://www.benzinga.com/government/regulations/24/11/41885393/germanys-govt-coalition-crisis-is-cannabis-reform-at-risk">remain on hold</a>. 
<ul>
<li>Read Next: <a href="https://www.benzinga.com/government/regulations/24/11/41884236/exclusive-persistence-pays-off-for-only-cannabis-distributor-in-bavarias-developing-market">EXCLUSIVE: Persistence Pays Off For Only Cannabis Distributor In Bavaria&#8217;s Developing Market</a></li>
</ul>
Cover: AI generated image

Eurozone

TLRY

Tilray Joins German Cannabis Fiesta With First Locally Grown Strains

Third Point, a hedge fund, filed its <a href="https://www.sec.gov/Archives/edgar/data/1656456/000165645624000004/xslForm13F_X02/Form13FInfoTable.xml">Form 13F</a> on Thursday, revealing the fund's trades from the prior quarter. Here's a look at Third Point's most <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41397978/hedge-fund-billionaire-daniel-loeb-bets-on-trump-win-singles-out-this-recent-buy-as">significant recent trades. </a>
New Positions: Third Point opened a total of nine positions during the quarter. The most notable are below.&nbsp;
<ul>
<li>Third Point added a stake in Brookfield Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with 4.725 million shares valued at $251.1 million, according to data from Whalewisdom. </li>
<li>The fund opened a position in Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with 400,000 shares. </li>
<li>Third Point opened a position in CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with 1,575,000 shares. </li>
</ul>
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock">Trump Media Insiders Sell More Than $16 Million In DJT Stock</a>
Closed Positions: The hedge fund closed out 11 positions with the most notable being American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) and its entire stake in Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>). 
Notable Trades: Third Point added 1,085,000 shares to its stake in Intercontinental Exchange Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), bringing its current position to 2,085,000 shares valued at $334.9 million, according to Whalewisdom. The fund reduced its stake in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) by 1,400,000 shares with 3,700,000 shares still held. 
Third Point also sold 555,000 Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) shares, more than half its stake in the company, but still holds 545,000 Meta shares valued at approximately $311.9 million, according to Whalewisdom.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Shutterstock

Hedge Funds

Third Point Hedge Fund Buys Tesla, Dumps Micron

In a market marked by mergers, acquisitions and growing consolidation, Garden Greens is not following the typical playbook. While large operators focus on the CPG model of uniformity and constant supply, Garden Greens takes a more adaptable approach by understanding demand cycles and responding creatively to consumer preferences.
As the industry undergoes massive consolidation, with big companies scooping up smaller players, Garden Greens stands out by keeping its product offerings fresh and exclusive. Rather than sticking to a fixed lineup, they frequently discontinue strains to build hype and create new demand.
In a time when the market favors the largest players, Garden Greens proves that a street-smart, flexible approach can help small and medium cannabis companies thrive.
Josh Krane, general manager at Garden Greens, brings a wealth of experience to the operation. With his roots in the hash-making business in Los Angeles, Krane has a deep understanding of the cannabis culture that many corporate operators lack. "You have to strip away all ego," he shared with Benzinga Cannabis, "and learn everything from the ground up."
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Beyond Standardization&nbsp;</h3>
Garden Greens operates under the principle that diversity and creativity are key to creating real demand. Krane's strategy is clear: "We're not just trying to scale. We're trying to build something<a href="https://www.benzinga.com/topic/cannabis-marketing"> consumers want</a>—something they've never had before."
At Garden Greens, running out of a strain isn&#8217;t a failure, it&#8217;s an opportunity to create excitement and engage consumers in a conversation. "We purposely let some strains go out of stock. We get more data from a strain being out of stock and consumers asking for it than from always having it available." 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41831831/no-middleman-no-markup-how-red-mesa-is-slashing-costs-with-around-the-clock-hemp-refinement"> No Middleman, No Markup: How Red Mesa Is Slashing Costs With Around-The-Clock Hemp Refinement</a>
<h3 class="wp-block-heading">The Power Of Genetics For Consumer Engagement&nbsp;</h3>
"We've released about 46 strains, and we deliberately let some go out of stock to build anticipation for new drops," says Krane.
The company runs nine flowering rooms and operates on a perpetual harvest cycle, allowing them to rotate and test new strains while ensuring consistent, high-quality output. &#8220;We're in perpetual harvest. We run about a nine-week flowering cycle. Every week, I have one room being harvested and then reset and replanted."
This perpetual harvest cycle ensures a steady supply of products while keeping the operation fluid and adaptable.
<a href="https://ggcann.com/">Garden Greens' flowering rooms</a> are designed for multi-cropping. At optimal capacity, they can handle up to four strains at a time. The company's strategy is to start with strains that have proven successful in other markets, strains they enjoy growing and smoking, and that will deliver predictable yields and potency.&nbsp;
Throughout a nine-week cycle, up to 36 strains can be tested and rotated through. Krane goes on to explain the rotation process: "We start layering those strains in, four at a time, a week at a time." Initially, they cycle in a set of 18 strains before introducing new ones for testing and evaluation.&nbsp;The company currently rotates major groups of genetics, all selected based on their similar growing needs. 
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41828889/exclusive-surviving-chavezs-venezuela-to-cbd-crash-ceo-reveals-how-to-profit-in-a-market-stuck-o">EXCLUSIVE: From Surviving Chavez&#8217;s Venezuela To The CBD Crash &#8211; CEO Reveals How To Profit In A Market Stuck On Repeat</a>
<h3 class="wp-block-heading">Fashion, Not CPG</h3>
Garden Greens has adopted a &#8220;fashion drop&#8221; mentality rather than trying to mirror<a href="https://www.benzinga.com/markets/cannabis/23/06/33061096/turnaround-potential-amazon-nestl-and-p-g-who-will-revive-dying-cannabis-brands"> CPG businesses</a> that focus on <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39469809/cannabis-vs-coca-cola-and-marlboro-marijuana-market-growth-outpaces-alcohol-tobacco">mass production</a> and brand consistency. The company builds anticipation before each <a href="https://www.benzinga.com/topic/cannabis-branding">new strain hits the market</a> by creating a sense of scarcity and exclusivity. "It's like a sneaker drop. We build up excitement for a product, and once it's gone, it's gone. We've built that by offering something they can't find anywhere else," Krane says.
<h3 class="wp-block-heading">Cash Flow Positive&nbsp;&nbsp;</h3>
The company relies on debt financing, with plans to repay investors within 24 months and switch to quarterly dividends afterward. "We've been able to stay cash flow positive and meet our financial goals while maintaining authenticity. We prioritize quality and innovation over cost-cutting measures that might please investors but compromise the product." 
Garden Greens' financial success stems from a combination of <a href="https://www.benzinga.com/markets/cannabis/24/09/40886620/how-this-former-dea-consultant-is-making-craft-cannabis-profitable-in-new-jersey-a-dirt-y-little">experienced workers and operational management </a>rolled with a smart approach to capital deployment. Krane and his team initially focused on infrastructure, construction, and culivation systems. 
Read Also:<a href="https://www.benzinga.com/general/biotech/24/10/41394513/sold-out-before-hitting-shelves-why-did-ayr-wellness-snatch-up-this-local-cannabis-brand"> Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?</a>
<h3 class="wp-block-heading">Price Is Right: Craft Cannabis Finds The Sweet Spot For Premium And Value</h3>
Krane's pricing strategy at Garden Greens is all about balance, catering to both high-end connoisseurs and budget-minded buyers. "We offer premium products that can sell for up to $140 per quarter, but we also provide more affordable options with our ‘Pete's Farmstand' line."
This dual-pricing model allows Garden Greens to appeal to a wide range of consumers. Limited-edition premium drops attract top-tier buyers, while the value line ensures accessibility without sacrificing quality.&nbsp;
The approach reflects Krane's deep understanding of the New Jersey market, where underground cannabis still influences price expectations. "I've seen top-shelf cannabis go for $150 or more in the underground scene," Krane notes, highlighting the competitive edge of Garden Greens&#8217; pricing.
Initially, the company aligned its premium prices with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41725186/with-200-new-dispensaries-and-four-states-voting-on-legalizing-cannabis-could-marke">multi-state operators (MSOs) to match established market expectations</a>. "We chose to match the MSO price points for premium cannabis to remain competitive," Krane says. This strategy positioned Garden Greens to compete head-on while still meeting quality standards.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41382006/hemp-thrives-in-texas-shops-near-schools-why-this-company-bet-on-the-countrys-most-regulated-can">Hemp Thrives In Texas Shops Near Schools: Why This Company Bet On The Country&#8217;s Most Regulated Cannabis Market</a>

Biotech

Market Summary

Entrepreneurship

Retail Sales

Startups

Exclusives

Selling Weed Is Like A Sneaker Drop: Running Out Isn't A Problem For This Company

Appaloosa Management filed its <a href="https://www.sec.gov/Archives/edgar/data/1656456/000165645624000004/xslForm13F_X02/Form13FInfoTable.xml">Form 13F</a> on Thursday, revealing the fund's trades from the prior quarter. Here's a look at Appaloosa's latest trades. 
New Positions:&nbsp;
<ul>
<li>Appaloosa added a stake in energy company Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with 1,270,388 shares valued at $150.5 million, according to Whalewisdom. </li>
<li>The fund added a stake in NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with 999,820 shares. </li>
<li>Appaloosa opened a position in Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with 1,528,323 shares</li>
<li>The hedge fund also opened a position in Wynn Resorts Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NYSE">WYNN</a>) with 800,000 shares. </li>
</ul>
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock">Trump Media Insiders Sell More Than $16 Million In DJT Stock</a>
Closed Positions: Appaloosa sold all of its 210,000 Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares. The fund also closed its entire positions in Macy's Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) and United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>). 
Notable Trades: Appaloosa added 3,361,132 shares of China-based commerce company PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), bringing its total stake to 5,301,132 shares valued at $617.4 million, according to Whalewisdom. The fund also added 2,989,400 shares of JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) another China-based commerce company. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Panchenko Vladimir on Shutterstock

Citigourp Global Markets 2% Protected Notes Linked To The Djia

WYNN

Appaloosa Hedge Fund Buys Vistra, Sells Boeing

Elliott Investment Management was busy in the third quarter. According to a new <a href="https://www.sec.gov/Archives/edgar/data/1048445/000156761920019906/0001567619-20-019906-index.htm">13-F</a> filing with the SEC, the activist made several portfolio moves, with multiple new positions focused around <a href="https://www.benzinga.com/news/24/10/41417317/southwest-airlines-in-settlement-talks-with-activist-investor-elliott-management-to-avoid-proxy-figh">travel and lodging</a>.
Here are all of Elliott&#8217;s new positions from the third quarter:
<ul>
<li>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</li>
</ul>
<ul>
<li>Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) call options</li>
</ul>
<ul>
<li>Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) call options</li>
</ul>
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) call options</li>
</ul>
<ul>
<li>Energy Select Sector SPDR Fund Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) call options</li>
</ul>
<ul>
<li>Alaska Air Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) call options</li>
</ul>
<ul>
<li>American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) call options</li>
</ul>
<ul>
<li>ICON Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) call options</li>
</ul>
<ul>
<li>IQVIA Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) call options</li>
</ul>
<ul>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) put options</li>
</ul>
<ul>
<li>Hilton Worldwide Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) put options</li>
</ul>
<ul>
<li>Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) put options</li>
</ul>
<ul>
<li>Hyatt Hotels Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) put options</li>
</ul>
<ul>
<li>Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) put options</li>
</ul>

Here&#8217;s a look at all of the positions Elliott increased during the third quarter:
<ul>
<li>Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) increased by 919%</li>
</ul>
<ul>
<li>Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) increased by 90%</li>
</ul>
<ul>
<li>Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) increased buy 11%</li>
</ul>
<ul>
<li>Match Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) increased by 3%</li>
</ul>

Here are all of the positions Elliott trimmed during the quarter:
<ul>
<li>BILL Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) decreased by 24%</li>
</ul>
<ul>
<li>BlackLine, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) decreased by 20%</li>
</ul>
<ul>
<li>Seadrill Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) decreased by 9%</li>
</ul>
<ul>
<li>NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) decreased by 7%</li>
</ul>
The above information does not include call or put options that were increased, trimmed or sold completely during the quarter. 
This information was gathered using comparison tools from <a href="https://13f.info/13f/000101359424000968/compare/000101359424000660">13f.info</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/hedge-funds/24/11/41995340/nelson-peltzs-trian-fund-management-reshaped-portfolio-ahead-of-presidential-election">Nelson Peltz&#8217;s Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election</a></li>
</ul>
Photo: Pixabay.

BILL

ETSY

ICLR

MTCH

SDRL

Elliott Investment Management Adds To Southwest, Western Digital, Etsy, Match Group; Trims BILL Holdings, Seadrill, BlackLine, NRG Energy In Q3

The Massachusetts Cannabis Control Commission issued new recommendations Wednesday through a bulletin designed to improve workplace health and safety at marijuana processing facilities and broadly across the legal industry.
The announcement represents the Commission's formal recognition of ground cannabis dust as a hazardous chemical that can irritate the respiratory system and exposed skin and marks a major step towards updating Massachusetts' workplace safety expectations following the <a href="https://www.benzinga.com/markets/cannabis/22/10/29130552/cannabis-employee-dies-from-inhaling-cannabis-dust-osha-report">2022 occupational asthma death of a Holyoke processing facility employee</a>.
"Today's bulletin is intended to bring increased awareness of an identified health risk in the marijuana industry and will support Commission and industry efforts to enhance safety standards across Massachusetts," stated commission acting executive director/chief people officer Debbie Hilton-Creek. "We will continue to partner with licensees to appropriately and effectively communicate this message and depend on them to implement protocols that will protect the overall well-being of our workforce."
Under the new bulletin, the Commission recommends that all licensees engaged in marijuana processing follow Occupational Safety and Health Administration (OSHA) guidelines around hazardous chemicals in the workplace. The Commission also reminds licensees of its obligation to have a hazard communication program which includes the evaluation of hazardous chemicals in its facility and develop Safety Data Sheets to inform its employees.
Going forward, the Commission is advising licensees engaged in marijuana processing to protect employees from hazards associated with cannabis dust exposure by using engineering controls like local exhaust ventilation, plus administrative controls like limiting employee exposure during the workday. The Commission recommends that licensees provide personal protective equipment, and appropriately manage medical situations when they arise.
What Happened: On Jan. 4, 2022, Lorna McMurrey (27) complained she could not breathe, presumably due to cannabis kief (cannabis dust) in the air where she was grinding and packaging pre-rolls. She was taken to a local hospital&nbsp;where she died on Jan. 7. According to the <a href="https://www.cdc.gov/mmwr/volumes/72/wr/mm7246a2.htm" target="_blank" rel="noreferrer noopener">report from</a> the Centers for Disease Control and Prevention (CDC), this was the first<a href="https://www.benzinga.com/markets/cannabis/23/11/35844553/cannabis-employee-died-from-occupational-asthma-fed-report-confirms-first-such-case-in-us" target="_blank" rel="noreferrer noopener"> known case of an occupational asthma death</a> in the U.S. cannabis industry. The report confirmed that the occupational asthma was triggered by ground cannabis dust, and revealed that cannabis giant Trulieve (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) committed three &#8220;serious&#8221; violations assessed by OSHA for which it paid fines totaling $35,219.
In June, the Commission fined medical marijuana giant Trulieve (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>) in relation to the death of a company&#8217;s employee in 2022. A company representative signed a tentative settlement with Commission, agreeing to a fine in the amount of $350,000.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/11/35915235/mother-of-deceased-cannabis-worker-sues-marijuana-giant-claiming-wrongful-death-and-negligence">Mother Of Deceased Cannabis Worker Sues Marijuana Giant Claiming Wrongful Death And Negligence</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Safety And Sanitary Standards</h2>
Today's update follows a state Department of Public Health (DPH) Fatality Assessment and Control Evaluation (FACE) report and Occupational Lung Disease Bulletin that were issued following McMurrey's death.
As the first confirmed case of&nbsp;occupational asthma in a cannabis facility, the CDC report said the incident&nbsp;"illustrates missed opportunities for prevention, including control of workplace exposures, medical surveillance, and treatment according to current asthma guidelines."&nbsp;
The previous DPH report also included recommendations for marijuana cannabis processors, including training all employees about how to work safely around hazardous materials, developing comprehensive health and safety programs, and monitoring employees for health symptoms.
The Commission's latest announcement relative to cannabis dust follows a February bulletin that advised licensees about new safety and sanitary standards for processing the leaves and flowers of female marijuana plants in a way that is:
<ul>
<li>Well cured and free from seeds and stems;</li>
<li>Free of dirt, sand, debris, and other foreign matter;</li>
<li>Free of contamination by mold, rot, other fungus, pests and bacterial diseases and satisfying the sanitation requirements in 105 CMR 500.000, and if applicable, 105 CMR 590.000: State Sanitary Code Chapter X – Minimum Sanitation Standards for Food Establishments;</li>
<li>Prepared and handled on food-grade stainless steel tables with no contact with Licensees' or Marijuana Establishment Agents' bare hands; and</li>
<li>Packaged in a secure area.</li>
</ul>
Commission's new bulletin clarifies that all licensees engaged in the processing of marijuana have a separate obligation to ensure the safety of workers, and all marijuana establishments and medical marijuana treatment centers in Massachusetts are required to follow Commission regulations that require written workplace safety and health standard operating procedures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41958902/hemp-co-wins-8-4m-grant-from-us-energy-dept-to-develop-carbon-negative-building-materials">Hemp Co. Wins $8.4M Grant From US Energy Dept. To Develop Carbon-Negative Building Materials</a></li>
</ul>
Photo: Courtesy of CRYSTALWEED cannabis on Unsplash

TCNNF

Ground Cannabis Dust Is A Hazardous Chemical, Confirms Massachusetts Regulator

Former Speaker Kevin McCarthy (R-Calif.) has expressed skepticism over the Senate confirmation of President-elect Trump&#8217;s nominee for attorney general, former Rep. Matt Gaetz (R-Fla.).
What Happened: McCarthy, a staunch Trump ally, voiced his doubts during a Bloomberg Television <a href="https://www.youtube.com/watch?v=WqzijZSqwXY&amp;ab_channel=BloombergTelevision">interview</a>. Despite his overall approval of Trump&#8217;s Cabinet picks, he singled out Gaetz, stating, &#8220;Gaetz won&#8217;t get confirmed. Everybody knows that.&#8221;
He also hinted at Gaetz&#8217;s lack of popularity within the Republican conference, implying that his nomination wouldn&#8217;t carry much weight.
&#8220;You'd have to ask the president, but Gaetz couldn't win in a Republican conference, so it doesn't matter.&#8221;
See Also: <a href="https://www.benzinga.com/24/11/41961161/musk-ramaswamy-headed-doge-department-will-be-an-incredibly-challenging-endeavor-says-ted-cruzshares-this-piece-of-advice?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Ted Cruz Says Running DOGE Won&#8217;t Be A Cake Walk, Offers Reading Advice To Elon Musk</a>
The nomination has caught many Senate Republicans off guard, with some expressing doubts about Gaetz&#8217;s potential confirmation. These concerns are likely to revolve around the Department of Justice&#8217;s previous investigation into allegations of sexual misconduct against Gaetz. Despite the investigation being closed last year without charges, the controversy could still affect the confirmation process.
Why It Matters: President-elect Trump&#8217;s nomination of Gaetz as attorney general, <a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">came as a surprise</a> to many. Gaetz, a controversial figure, is known for his radical proposals, including a bill to allow federal <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41964758/trumps-attorney-general-pick-matt-gaetz-once-proposed-collecting-federal-income-taxes-in-bitcoin-apart-from-co-sponsoring-bill-to-abolish-the-fed">income tax payments</a> in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
The relationship between McCarthy and Gaetz has been fraught with tension. Gaetz <a href="https://www.benzinga.com/news/23/10/35043900/matt-gaetz-challenges-kevin-mccarthys-leadership-response-from-the-house-speaker-bring-it-on">led an effort</a> to remove McCarthy from his speakership position. McCarthy has <a href="https://www.benzinga.com/news/24/04/38175658/kevin-mccarthy-ties-gaetzs-sexual-misconduct-allegations-to-his-speaker-ouster">linked his removal</a> from the Speaker position to the sexual misconduct allegations against Gaetz.
Photo by Consolidated News Photos on Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Kevin McCarthy Says Matt Gaetz Won't Get Confirmed By The Senate And 'Everybody Knows That'

A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election.
Third Quarter Exits: Viking Fund Management sold out of eight stocks completely in the third quarter, including positions in some of the largest oil companies.
Here are the positions exited, as <a href="https://13f.info/13f/000116906924000080/compare/000116906924000006">reported </a>by 13finfo:
<ul>
<li>Marathon Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)</li>
<li>Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>)</li>
<li>SM Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>)</li>
<li>Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>)</li>
<li>Sociedad Quimica y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>)</li>
<li>Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)</li>
<li>Sanofi SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>)</li>
<li>Cactus Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>)</li>
</ul>
Third Quarter New Positions: The following were the new stocks added to the fund in the third quarter, ranked in size by the dollar value at the end of the quarter.
<ul>
<li>Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>)</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</li>
<li>HF Sinclair Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>)</li>
<li>Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>)</li>
<li>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</li>
<li>Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</li>
<li>Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>)</li>
<li>Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</li>
<li>United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>)</li>
<li>Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>)</li>
<li>Portland General Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</li>
<li>Restaurant Brands International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>)</li>
<li>Nutrien (NTR.TO – Canada)</li>
</ul>
 Big Moves: The fund made several changes to its existing positions alongside the new positions and exited positions.
Here are the biggest additions in the quarter to existing stakes:
<ul>
<li>Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>): +16,900%</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): +882%</li>
<li>LyondellBassell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): +400%</li>
<li>Rio Tinto PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>): +386%</li>
<li>Dow Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): +200%</li>
</ul>
Here are the biggest position cuts during the quarter to existing stakes:
<ul>
<li>Texas Pacific Land (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>): -60%</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): -50%</li>
<li>Haliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>): -40%</li>
<li>ExxonMobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): -36%</li>
<li>Ovintiv (OVV.TO – Canada): -33%</li>
</ul>
Why It's Important: At the end of the quarter, these are the fund's largest positions ranked by dollar value and the percentage they make up of the fund:
<ul>
<li>Broadcom: $27.96 million, 4.5%</li>
<li>AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): $24.88 million, 4.0%</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): $22.65 million, 3.7%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): $16.27 million, 2.6%</li>
<li>BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): $14.24 million, 2.3%</li>
</ul>
The fund added significantly to its position in Broadcom, which remains the largest holding.
The quarter saw the sale of several oil stocks, but the fund opened new positions in several energy names in the quarter.
Photo: Shutterstock

ABBV

AVGO

CIVI

DINO

GTLS

MUSA

SCCO

SHEL

WFRD

Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom

Dividends

Nike Raised Quarterly Dividend From $0.37 To $0.40

The pre-roll market, now surpassing $1.5 billion in annual sales, has become one of the fastest-growing and most competitive segments in cannabis. With a flood of brands vying for consumer attention, standing out in this sea of products is no easy feat. Custom Cones USA, however, is tackling this challenge head-on.&nbsp;
By offering pre-roll solutions at scale, they're helping businesses navigate the crowded market and find their niche.
But it's not just about volume. Custom Cones USA is setting itself apart with innovations like cannabis humidors, designed to keep products fresher for longer—a critical factor in ensuring quality and building consumer trust. As CEO Harrison Bard shared with Benzinga Cannabis, the company's mission is clear: to fuel the growth of the pre-roll category while giving brands the tools they need to thrive.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Custom Made: Glass Tips, Flavored Tips, And… Fusilli Noodle Tips</h3>
With dispensary shelves overflowing, how can brands truly stand out? Is it possible to balance large-scale production with unique, artisanal designs? Custom Cones USA has built its reputation on flexibility, offering tailored solutions to meet diverse client needs.&nbsp;
Bard shared some of the more unusual requests they've received over the years, including a proposal for filter tips shaped like fusilli noodles. "We considered it, but the concerns around food import regulations and potential insect issues made us decline," Bard noted with a laugh.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046-1024x683.jpg" alt="" class="wp-image-641591" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184321/CCUSA_Custom-Branded-Pre-Rolls_1UP_046.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Courtesy of Custom Cones USA</figcaption></figure>
Beyond the quirky requests, the company offers a wide range of customization options, from colored tips and designer cones in various shades to themed products for holidays and special events.&nbsp;
They also provide ceramic and glass filter tips for premium offerings, allowing brands to elevate their pre-rolls with distinct, high-quality touches. "We can accommodate everything from small, bespoke orders for craft farms to bulk shipments for large MSOs, giving our clients the flexibility they need to differentiate their products," Bard explained.
Read Also:<a href="https://www.benzinga.com/news/24/09/40941818/how-this-cheese-aging-tech-is-boosting-profits-for-cannabis-growers-stop-throwing-cheddar-out-the-do"> How This Cheese-Aging Tech Is Boosting Profits For Cannabis Growers: Stop Throwing Cheddar Out The Door</a>
<h3 class="wp-block-heading">Supply Chain And Design Rolled Into One&nbsp;</h3>
Operating in a<a href="https://www.benzinga.com/markets/cannabis/24/10/41523813/cannabis-pre-rolls-set-to-hit-4-billion-by-2025-will-us-market-follow-canadas-lead"> high-demand market</a>, Custom Cones USA has faced unique supply chain challenges, particularly with niche products. Thus, the company maintains a robust inventory of core items like 109mm, 98mm, and 84mm cones, often holding two to three months of supply domestically.&nbsp;
In response to the increasing demand for custom designs, Custom Cones USA offers a graphic design service that streamlines the process for clients.&nbsp;
Bard explained, "We provide a full design service or support clients who prefer using tools like Canva. As long as they can provide a vector file, we handle the rest." This flexibility allows small businesses and large operators alike to create unique branded products without excessive lead times or high minimum orders.
<h3 class="wp-block-heading">Pre-Rolls For All&nbsp;</h3>
Innovative products like ceramic and glass filter tips, along with flavored wooden tips, are part of the company's strategy to meet evolving consumer preferences. "We're seeing a growing interest in premium tip sections, and we're the only company offering these high-quality, in-stock options," Bard explained.
From bespoke color-tip cones for small craft brands to large-scale orders for major multi-state operators (MSOs), Custom Cones USA caters to a wide range of clients. "We offer the lowest minimum order quantities in the industry, making it accessible for both small mom-and-pop shops and large MSOs," Bard said.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004-1024x683.jpg" alt="" class="wp-image-641592" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004-1024x683.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004-300x200.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004-768x512.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004-1536x1024.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184352/CCUSA_Custom-Branded-Pre-Rolls_1UP_004.jpg 1620w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Looking ahead, Custom Cones USA is making a significant pivot towards consumer products. The company launched DaySavers, a brand focused on providing safe, compliant smoking accessories.&nbsp;
"There are no regulations for smoking accessories like blunt wraps or palm leaf products, which often fail tests for heavy metals and pesticides," Bard pointed out. DaySavers aims to fill this gap, offering products that are independently tested to meet safety standards.
Read Also:<a href="https://www.benzinga.com/general/biotech/24/08/40298228/think-you-can-do-it-all-20-000-reasons-why-automation-outperforms-a-broad-approach-in-cannabis"> Think You Can Do It All? 20,000 Reasons Why Automation Outperforms A Broad Approach In Cannabis</a>
<h3 class="wp-block-heading">Fresh Lettuce&nbsp;</h3>
Bard highlighted Custom Cones will be bringing a <a href="https://www.benzinga.com/markets/cannabis/24/06/39508155/900-pre-rolls-per-hour-upgrade-from-manual-to-automatic-speeds-up-joint-production-enhances-marg">significant innovation for the cannabis industry</a>: the adoption of humidors.&nbsp;
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="1000" height="1000" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184105/Humidor_2024_012.jpg" alt="" class="wp-image-641587" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184105/Humidor_2024_012.jpg 1000w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184105/Humidor_2024_012-300x300.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184105/Humidor_2024_012-150x150.jpg 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11184105/Humidor_2024_012-768x768.jpg 768w" sizes="(max-width: 1000px) 100vw, 1000px" /><figcaption class="wp-element-caption">Courtesy of Custom Cones USA</figcaption></figure>
"<a href="https://customconesusa.com/black-series-humidor-1310-perfect-for-cannabis-pre-roll-blunts-and-hemp-wraps/">Humidors</a> are already common in cigar shops, and we see a similar trend emerging for cannabis," Bard shared.&nbsp;
Custom Cones USA recently launched a line of cannabis humidors, which Bard believes could become a standard feature in dispensaries within the next decade. These devices help maintain freshness and could potentially reduce the need for airtight, less eco-friendly packaging.
The company is also exploring new infusion technologies. "We're excited about the possibilities of bringing<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products"> infused</a> papers back into our portfolio, as it aligns with our commitment to innovation and quality," Bard revealed.
As the holiday season approaches, Custom Cones USA is ramping up its efforts to meet demand.&nbsp;
"Our preparation involves maintaining a strong inventory and leveraging advanced logistics," Bard explained. "Our flavored cones and premium ceramic tips have been particularly popular, and we anticipate even higher demand this year," he concluded.&nbsp;
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/09/40972472/x-rays-microwaves-and-now-what-this-company-freezes-weed-at-320-f-to-kill-mold-and-save-a-ton"> X-Rays, Microwaves And Now What? This Company Freezes Weed At -320°F To Kill Mold And Save A Ton</a>

Contracts

Management

Success Stories

Small Business

Can Pre-Roll Humidors Save Your Cannabis Brand? Custom Cones USA Says Yes

Cue Biopharma prices $12M stock offering

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Cue Biopharma stock rallies nearly 40% on upcoming presentations

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Cue Biopharma (CUE) presented updated data from its Phase 1 dose escalation and expansion trial evaluating its lead oncology asset from the Immuno-...

Cue Biopharma presents 'positive' update from Phase 1 trials of CUE-101, CUE-102

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target...

Cue Biopharma: Strategic Shift and Promising Clinical Results Support Buy Recommendation

Cue Biopharma (CUE) announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer effective November 25, 2024. Dr...

Cue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor role

Cue names Daniel Baker interim CDO, CSO Anish Suri to transition to advisor role

Reports Q3 revenue $3.34M, consensus $1.52M. "We are very pleased with the validating updated clinical data from our Phase 1 trials for both CUE-10...

Cue Biopharma reports Q3 EPS (17c), consensus (19c)

ABUS

ALLK

ALPMF

ALPMY

ANTX

APVO

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CNSP

CRBU

CVAC

CYCC

ELAB

FGEN

GLYC

GNPX

HLVX

IBRX

IMUX

INAB

LXRX

MBIO

ONCT

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

SYRS

VIRX

Press Releases

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Financing

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Comments

Cue Biopharma

Notizie

Ultime notizie per Cue Biopharma (NASDAQ:CUE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO